evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract
18728,GENE_SUMMARY,,"SPOP encodes an adaptor protein involved in targeting proteins for degradation. SPOP mutations are predominantly found in prostate and endometrial cancers; however, the full functional consequence of these mutations remains under investigation.",,2017-03-22,,8405,SPOP,speckle type BTB/POZ protein,False,ENST00000347630,NM_001007228.1,TEF2,BTBD32,True,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18729,GENE_BACKGROUND,,"The SPOP (Speckle-type POZ protein) gene encodes a protein which is part of the CUL3 ubiquitin ligase complex. SPOP contains a nuclear localization sequence, a BTB (Bric-a-brac/Tramtrack/Broad complex) domain that mediates dimerization and interaction with CUL3, and a MATH domain that recognizes substrates for ubiquitination (PMID: 19818708). The repertoire of SPOP substrates is not well characterized; however, notable proteins include SRC3, DAXX, H2AFY, AR, BMI1, DEK, ESR1 and TRIM24 (PMID: 25278611, 15897469, 25274033, 21577200, 25766326). Point mutations in SPOP are reported in approximately 5% of endometrial cancers (PMID: 23104009) and 10% of prostate cancers (PMID: 21307934, 22610119). SPOP mutations in both endometrial and prostate cancer cluster in conserved residues of the MATH domain, suggesting that the mutations either alter substrate recognition or act as a dominant negative to prevent substrate degradation. Interestingly, the mutations found in endometrial cancer do not overlap with mutations found in prostate cancer, suggesting that they may have distinct functions. SPOP mutations in prostate cancer are always missense, heterozygous and the wildtype allele is always expressed, suggesting that it may have a gain-of-function or dominant negative function. In contrast, some SPOP mutations in endometrial cancer are associated with loss of the wild-type allele, while others are frame-shift or nonsense mutations, suggesting that they are inactivating. There is emerging evidence that SPOP may be a more general tumor suppressor in glioblastoma, gastric and colorectal cancers, as SPOP expression is decreased through tumor progression (PMID: 25351530, 23216165). However, more definitive evidence such as mutations or copy number loss is not observed in these tumor types.",,2017-03-22,,8405,SPOP,speckle type BTB/POZ protein,False,ENST00000347630,NM_001007228.1,TEF2,BTBD32,True,25278611,Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.,"Science (New York, N.Y.)",2018-10-03T20:14:00,346,6205,85-89,Theurillat JP et al,doi: 10.1126/science.1250255,,0001-10-03,,19818708,Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases.,Molecular cell,2018-10-09T20:09:00,36,True,39-50,Zhuang M et al,doi: 10.1016/j.molcel.2009.09.022,,0001-10-09,,21307934,The genomic complexity of primary human prostate cancer.,Nature,2018-02-10T20:11:00,470,7333,214-20,Berger MF et al,doi: 10.1038/nature09744,,0001-02-10,,25351530,Decreased expression of the SPOP gene is associated with poor prognosis in glioma.,International journal of oncology,2018-01-01T20:15:00,46,True,333-41,Ding D et al,doi: 10.3892/ijo.2014.2729,,0001-01-01,,23104009,Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes.,Nature genetics,2017-12-01T20:12:00,44,12,1310-5,Le Gallo M et al,doi: 10.1038/ng.2455,,0001-12-01,,22610119,"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.",Nature genetics,2018-05-20T20:12:00,44,6,685-9,Barbieri CE et al,doi: 10.1038/ng.2279,,0001-05-20,,25766326,Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover.,Cell death &amp; disease,2018-03-12T20:15:00,6,,e1687,Zhang P et al,doi: 10.1038/cddis.2015.47,,0001-03-12,,23216165,"Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers.","APMIS : acta pathologica, microbiologica, et immunologica Scandinavica",2018-07-01T20:13:00,121,7,626-33,Kim MS et al,doi: 10.1111/apm.12030,,0001-07-01,,15897469,Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase.,Proceedings of the National Academy of Sciences of the United States of America,2018-05-24T20:05:00,102,21,7635-40,Hernández-Muñoz I et al,,,0001-05-24,,21577200,Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1.,Oncogene,2018-10-20T20:11:00,30,42,4350-64,Li C et al,doi: 10.1038/onc.2011.151,,0001-10-20,,25274033,Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.,Cancer research,2018-10-01T20:14:00,74,19,5631-43,Geng C et al,doi: 10.1158/0008-5472.CAN-14-0476,,0001-10-01,
